Transgenic Drosophila AD models have been employed for a number of drug testing studies involving different targets such as AChE, GSK-3β, lysozyme, radiation, Tau protein, and dopaminergic receptors (Sandin et al., 2016; Zhang et al., 2016a; Pham et al., 2018; Ali et al., 2019; Hwang et al., 2019; Miyazaki et al., 2019; Zhong et al., 2019). The gene discussed is GSK3B; the disease is Alzheimer disease.